Apollo Hospitals Enterprise Ltd Forensic Report - SOIC x StockScans Report

as of Sep 2026

Apollo Hospitals' financial record is built on stable auditor relationships and a clean regulatory history, but the FY2026 audit reveals a group under sustained pressure: a land asset under government cancellation, a widening pattern of audit-trail exceptions, and debt that sits outside the reported gearing ratio.

Key findings

  1. A ₹109.73 crore land asset is under government cancellation and litigation Major - Karnataka's Revenue Department cancelled the IHRCL land grant on February 13, 2026, alleging alienation via share purchase; the Karnataka High Court granted an interim stay on April 10, 2026. Land and building of ₹19 crore and ₹90.73 crore relate to IHRCL as at March 31, 2026. The same Emphasis of Matter, a special call-out in the audit report, has appeared in every consolidated report since FY2020.
  2. Audit-trail exceptions have widened from a single gap to a group-wide pattern Major - The FY2026 consolidated audit report lists ten distinct audit trail exception categories covering the Parent, at least 15 subsidiaries, one associate and one JV. The standalone report notes the audit trail feature was not enabled at database level for the hospitals division's accounting software from 1 April 2025 to 24 June 2025. The auditor nonetheless concluded internal controls over financial reporting operated effectively for the year ended 31 March 2026.
  3. Reported 46% gearing includes CCPS but excludes lease liabilities Major - Apollo Healthco Limited issued CCPS shares against receipt of ₹2,475 crore in FY2024-25, classified entirely as liability. A ₹683.5 crore put-option liability was reversed to retained earnings upon extinguishment during FY2025-26. The group's gearing ratio was 46% at March 31, 2026, below the 100% target.
  4. Goodwill has never been impaired in seven years, while smaller investments in the same entities are repeatedly impaired Major - Management concluded no impairment of goodwill in any CGU in FY2020 through FY2026. Apollo recognised goodwill of ₹537.1 crore on acquiring the remaining 50% of Apollo Multispeciality Hospitals in April 2021. The standalone entity recognised impairment in investments in Apollo Lavasa and Stemcyte in FY2022, FY2023 and FY2026.
  5. Common-control reorganisations and exceptional-item classification have repeatedly reshaped reported profit and reserves Major - Apollo recognised an exceptional gain of ₹294.1 crore on remeasurement of its existing stake when acquiring the remaining 50% of Apollo Multispeciality Hospitals. A ₹283.2 crore excess of consideration over net assets was transferred to capital reserve in a common-control transaction. A Composite Scheme of Arrangement approved June 30, 2025 provides for demerger of the pharmacy and digital business into Apollo Healthtech Limited.
  6. The group is in continuous reorganisation, with control over two entities resting on contractual arrangements Major - Apollo Hospitals International Limited is consolidated despite only 50% ownership, based on contractual rights to appoint key management and approve the business plan. AHEL acquired the entire minority interest in AHLL in March 2026 for ₹1,272.8 crore. The Board approved on May 20, 2026 a proposal for AHLL to combine with Kids Clinic India Ltd, subject to CCI approval.
  7. Revenue quality is pressured by credit-loss provisions and a concentrated digital distribution channel Major - The Digital Health & Pharmacy Distribution segment sells entirely to Apollo Pharmacies Limited, an associate. The consolidated expected credit loss allowance on trade receivables was ₹2,544 million (₹254.4 crore) as at March 31, 2026. Management revised digital business cash EBITDA breakeven from Q4 FY26 to Q1 FY27, citing an insurance revenue recognition mismatch.
  8. The regulatory record is clean, with only minor resolved penalties Clean - The Board's Report states no significant material orders were passed by Regulators or Courts impacting going concern status. Fees of ₹10,000 each were paid to NSE and BSE for a 2020 intimation omission. An NSE penalty for a board composition gap was paid on 26 November 2021.
  9. Deloitte has served since 2017 with no resignations or qualifications, in its final term ending 2027 Clean - Deloitte Haskins & Sells LLP was re-appointed at the 41st AGM in August 2022 for a second and final term ending at the 46th AGM in 2027. The FY2025-26 audit report was unmodified, with no qualification or adverse remark. Total fees to the auditor and network firms were ₹8.9 crore in FY2025-26.

What to watch

Bottom line: This is a disclosed and audited record with a stable auditor and a clean regulatory history. The risk sits in the gap between what is reported and what is disclosed: debt outside the gearing ratio, a land asset under active cancellation, and a group structure in constant motion. Read the audit-trail exceptions and the related-party flows with that in mind, and watch the court and regulatory decisions ahead.